What is the 13F Pro Quality Score for KYMR?

13F Pro ranks Kymera Therapeutics, Inc. (KYMR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View KYMR's current score at https://13fpro.ai/company/KYMR (free sign-up required for the full ranking).

Which hedge funds own the most KYMR stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of KYMR include FMR, BAKER BROS. ADVISORS, Avoro Capital Advisors. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/KYMR as soon as new 13F filings post.

Where does 13F Pro source KYMR data?

All Kymera Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Kymera Therapeutics, Inc. files with the SEC under CIK 1815442. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is KYMR in?

Kymera Therapeutics, Inc. (KYMR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is KYMR research updated on 13F Pro?

KYMR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Kymera Therapeutics, Inc.(KYMR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1815442 KYMR stock profile & AI dashboard →

13F Pro Quality Score

28.4/100

Rank #2,557 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

89.9/100

Profitability

4.5/100

Balance Sheet

10.5/100

Earnings Quality

23.5/100

Free Cash Flow

4.1/100

Institutional Flow

46.8/100

Revenue Scale

16.5/100

Dilution Risk

2.2/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why KYMR Scores 28/100

exact factor attribution · 2026-09-11

KYMR's composite is driven by revenue growth, held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+8.0 pts

90th pct

Institutional flow

-0.2 pts

47th pct

Earnings growth

-1.7 pts

16th pct

Shareholder dilution

-2.4 pts

2th pct

Earnings quality

-2.6 pts

24th pct

Capital efficiency

-4.0 pts

11th pct

Scale

-5.0 pts

17th pct

Profitability

-6.8 pts

5th pct

Free cash flow

-6.9 pts

4th pct

Latest change (2026-08-05): 29 → 12 · ↓ Revenue growth 88→5

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in KYMR

Events flagged as statistical outliers against KYMR's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-05
KYMR quality score dropped 18 points (29→12) on a new filing
View source filing →

KYMR Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Kymera Therapeutics, Inc. (KYMR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KYMR at 28.4/100 on a 32-signal composite quality model, placing it at rank #2,557 of 2,961 stocks — the bottom half of the AI-ranked universe. KYMR scores in the top quartile across revenue growth (89.9). Areas of concern include free cash flow (4.1) and profitability (4.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Kymera Therapeutics, Inc. reports quarterly revenue of $65.0M, net income of $-61.2M, free cash flow of $-54.5M. Top institutional holders of KYMR by reported 13-F value include FMR, BAKER BROS. ADVISORS, Avoro Capital Advisors, based on the most recent SEC filings. KYMR trades on the Nasdaq exchange and files with the SEC under CIK 1815442. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KYMR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Kymera Therapeutics, Inc. directly from SEC EDGAR. Kymera Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 8 and 55 since 2021, currently 28.4 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about Kymera Therapeutics, Inc.

Quirks, history, and lore behind KYMR — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Massachusetts · focused on a cutting-edge class of drugs that makes unwanted proteins simply disappear.
2
The Numbers
A small-cap biotech with no approved products yet, burning through cash on R&D — a totally normal Tuesday in drug development. Pipeline, not profit, is the whole pitch.
3
The History
Founded around 2016, the company emerged from the Boston biotech ecosystem riding a then-nascent scientific wave called targeted protein degradation — essentially teaching cells to take out their own trash.
4
The Secret
Its platform exploits the cell's own ubiquitin-proteasome system — a natural garbage-disposal pathway — to tag and destroy disease-causing proteins that traditional drugs can't touch.
5
The Lore
The company's name is a nod to chimera, the mythological beast stitched together from different creatures — fitting for drugs that are molecular hybrids designed to hijack cellular machinery.
6
The Giveaway
It's one of the leading pure-play protein degrader biotechs, building so-called degrader antibody conjugates and small-molecule degraders — its ticker even sounds like a creature from another world.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$65.0M

Net Income

Q2 2026

$-61.2M

Free Cash Flow

Q2 2026

$-54.5M

ROIC

Q2 2026

-20.0%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-16.7% YoY

$39.2MFY 2025

FY22 $46.8MFY23 $78.6MFY24 $47.1MFY25 $39.2M

Net Income

-39.1% YoY

$-311.4MFY 2025

FY22 $-154.8MFY23 $-147.0MFY24 $-223.9MFY25 $-311.4M

Operating Income

-33.5% YoY

$-349.4MFY 2025

FY22 $-161.3MFY23 $-165.5MFY24 $-261.6MFY25 $-349.4M

EPS (Diluted)

-23.8% YoY

$-3.69FY 2025

FY22 $-2.87FY23 $-2.52FY24 $-2.98FY25 $-3.69

Total Assets

+78.2% YoY

$1.74BFY 2025

FY22 $603.1MFY23 $575.8MFY24 $978.0MFY25 $1.74B

Op. Cash Flow

-19.7% YoY

$-232.9MFY 2025

FY22 $-153.1MFY23 $-102.8MFY24 $-194.5MFY25 $-232.9M

Free Cash Flow

-13.0% YoY

$-234.3MFY 2025

FY22 $-155.9MFY23 $-137.3MFY24 $-207.3MFY25 $-234.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$39.2M -16.7%	$47.1M -40.1%	$78.6M +67.8%	$46.8M -35.7%	$72.8M +114.0%	$34.0M
Net Income	$-311.4M -39.1%	$-223.9M -52.3%	$-147.0M +5.1%	$-154.8M -54.5%	$-100.2M -119.8%	$-45.6M
Operating Income	$-349.4M -33.5%	$-261.6M -58.1%	$-165.5M -2.7%	$-161.3M -60.4%	$-100.5M -117.1%	$-46.3M
EPS (Diluted)	$-3.69 -23.8%	$-2.98 -18.3%	$-2.52 +12.2%	$-2.87 -37.3%	$-2.09 +33.7%	$-3.15
Total Assets	$1.74B +78.2%	$978.0M +69.9%	$575.8M -4.5%	$603.1M -0.5%	$605.9M +24.4%	$487.2M
Operating Cash Flow	$-232.9M -19.7%	$-194.5M -89.2%	$-102.8M +32.8%	$-153.1M -18.7%	$-128.9M -246.3%	$88.1M
Free Cash Flow	$-234.3M -13.0%	$-207.3M -51.0%	$-137.3M +11.9%	$-155.9M -19.4%	$-130.5M -265.2%	$79.0M

Get alerted when KYMR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Kymera Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of KYMR

FMR LLC
$1.4B12,349,256 sh
BAKER BROS. ADVISORS LP
$992.7M8,657,242 sh
Avoro Capital Advisors LLC
$857.1M7,474,747 sh
PRICE T ROWE ASSOCIATES INC /MD/
$815.6M7,112,980 sh
T. Rowe Price Investment Management, Inc.
$717.5M6,257,261 sh
BlackRock, Inc.
$635.1M5,538,210 sh
BVF INC/IL
$444.0M3,872,052 sh
WELLINGTON MANAGEMENT GROUP LLP
$421.4M3,675,028 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$343.1M2,992,193 sh
Siren, L.L.C.
$336.7M2,935,830 sh

Fund	Value	Shares
FMR LLC	$1.4B	12,349,256
BAKER BROS. ADVISORS LP	$992.7M	8,657,242
Avoro Capital Advisors LLC	$857.1M	7,474,747
PRICE T ROWE ASSOCIATES INC /MD/	$815.6M	7,112,980
T. Rowe Price Investment Management, Inc.	$717.5M	6,257,261
BlackRock, Inc.	$635.1M	5,538,210
BVF INC/IL	$444.0M	3,872,052
WELLINGTON MANAGEMENT GROUP LLP	$421.4M	3,675,028
VANGUARD PORTFOLIO MANAGEMENT LLC	$343.1M	2,992,193
Siren, L.L.C.	$336.7M	2,935,830

Companies Similar to KYMR

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

CYTK

CYTOKINETICS INC

AI score

Very similar · 28 shared holders

T. Rowe Price Investment Management, Inc.Avoro Capital Advisors LLC Capital Research Global Investors

RYTM

RHYTHM PHARMACEUTICALS, INC.

AI score

Very similar · 30 shared holders

BAKER BROS. ADVISORS LP Capital Research Global Investors Siren, L.L.C.

VRDN

Viridian Therapeutics, Inc.\DE

AI score

Very similar · 17 shared holders

Avoro Capital Advisors LLC BAKER BROS. ADVISORS LP Candriam S.C.A.

MIRM

Mirum Pharmaceuticals, Inc.

AI score

Very similar · 26 shared holders

BVF INC/IL EVENTIDE ASSET MANAGEMENT, LLC BAKER BROS. ADVISORS LP

TNGX

Tango Therapeutics, Inc.

AI score

Very similar · 25 shared holders

Siren, L.L.C.Holocene Advisors, LP Boxer Capital Management, LLC

CRNX

Crinetics Pharmaceuticals, Inc.

AI score

Very similar · 20 shared holders

DRIEHAUS CAPITAL MANAGEMENT LLC BAKER BROS. ADVISORS LP T. Rowe Price Investment Management, Inc.

CGON

CG Oncology, Inc.

AI score

Very similar · 23 shared holders

T. Rowe Price Investment Management, Inc.Clearbridge Investments, LLC RTW INVESTMENTS, LP

MDGL

MADRIGAL PHARMACEUTICALS, INC.

AI score

Very similar · 28 shared holders

BAKER BROS. ADVISORS LP Avoro Capital Advisors LLC Holocene Advisors, LP

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put KYMR on your watchlist

Track score changes the day Kymera Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is KYMR a good stock to buy?

13F Pro's AI-powered analysis of Kymera Therapeutics, Inc. (KYMR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KYMR are available on the KYMR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. KYMR is classified as a mid company.

Which hedge funds own KYMR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KYMR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Kymera Therapeutics, Inc.'s investment landscape.